Initial Glycemic Management for Newly Diagnosed Type 2 Diabetes With A1c 9.8%
For most adults with type 2 diabetes, initial glucose-lowering therapy should be combined with lifestyle modification, and metformin is a commonly used first-line medication when no contraindication is present. [1] Initiation of insulin should be considered when symptoms of hyperglycemia are present or when A1c is >10% or glucose is ≥300 mg/dL. [1] With an A1c of 9.8%, A1c is below the ADA threshold that automatically favors insulin initiation in asymptomatic patients. [1]
Medication Selection Algorithm
Metformin is a first-line option for initial glucose-lowering therapy in adults with type 2 diabetes. [1]
Selection of additional therapy beyond metformin should incorporate comorbidities and hypoglycemia risk. [1]
Preferred medication classes to consider for added glycemic efficacy and cardiorenal benefit include:
- GLP-1 receptor agonists (including dual GIP and GLP-1 receptor agonists). [1]
- SGLT2 inhibitors. [1]
Other noninsulin glucose-lowering options may be selected based on patient factors, including:
- DPP-4 inhibitors. [1]
- Thiazolidinediones. [1]
- Sulfonylureas or other agents with higher hypoglycemia risk when appropriate. [1]
Treatment Initiation Thresholds
Insulin initiation should be considered when any of the following are present:
- Symptoms of hyperglycemia. [1]
- A1c >10% (86 mmol/mol). [1]
- Blood glucose ≥300 mg/dL (16.7 mmol/L). [1]
Initial combination therapy should be considered when A1c is 1.5–2.0% above the individualized glycemic goal. [1]
Monotherapy Versus Combination Therapy
Metformin monotherapy can be initiated when A1c is near the individualized goal. [1]
Initial combination therapy should be considered for patients presenting with A1c levels substantially above the individualized goal. [1]
If insulin is used, combination therapy with a GLP-1 receptor agonist (including dual GIP and GLP-1 receptor agonists) is recommended for greater glycemic effectiveness with beneficial effects on weight and hypoglycemia risk. [1]
Practical Outpatient Treatment Plan for A1c 9.8%
Lifestyle therapy should be started concurrently with pharmacologic therapy. [1]
Metformin should be initiated unless contraindicated. [1]
Additional therapy should be added when A1c is 1.5–2.0% above the individualized glycemic goal. [1]
When no need for insulin is present by ADA insulin-activation criteria, added therapy commonly includes one of the following class targets:
- GLP-1 receptor agonist (including dual GIP and GLP-1 receptor agonists). [1]
- SGLT2 inhibitor. [1]
- Alternative noninsulin agent selected based on comorbidities and hypoglycemia risk. [1]
Target Blood Pressure and Glycemic Goals
For most adults, the A1c treatment goal is <7%. [2]
Achievement of lower A1c levels than 7% may be acceptable when attainable safely without frequent or severe hypoglycemia or adverse effects. [2]
Monitoring and Reassessment
Medication intensification should be guided by response to therapy and attainment of individualized glycemic goals. [1]
Reassessment of the need for or dose of higher hypoglycemia-risk medications should occur when initiating new glucose-lowering medication. [3]
Key Clarifications for This A1c Level
An A1c of 9.8% meets criteria for consideration of initial combination therapy when the individualized goal is ~7%. [1]
Insulin is not required solely on the basis of A1c 9.8% in the absence of symptoms of hyperglycemia and without glucose ≥300 mg/dL, because ADA’s insulin-consideration threshold for very high A1c is >10%. [1]
Lifestyle modification should be emphasized as part of management with any pharmacologic regimen. [1]